NORD joins a one pager with other patient advocacy organizations in support of Arizona’s House Bill 2144 on biomarker testing coverage
Published: Jan 25, 2022
Tagged in: Access to Innovative Medicines and Therapies, Gene Therapies
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD joins a one pager with other patient advocacy organizations in support of Arizona’s House Bill 2144 on biomarker testing coverage
Published: Jan 25, 2022
Tagged in: Access to Innovative Medicines and Therapies, Gene Therapies
NORD Submits Comments to the National Center for Advancing Translational Sciences (NCATS) RFI on Facilitating the Early Diagnosis and Equitable Delivery of Gene-Targeted Therapies to Individuals with Rare Diseases
Published: Jun 30, 2021
Tagged in: Gene Therapies, Advancing Rare Disease Research and Regulatory Science
NORD submits comments on FDA Draft Guidance on Interpreting Sameness for Gene Therapy Products Under the Orphan Drug Regulations
Published: Jul 28, 2020
Tagged in: Gene Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act
NORD comments to FDA regarding gene therapies for rare diseases
Published: Dec 14, 2018
Tagged in: Access to Innovative Medicines and Therapies, Gene Therapies